Amalgamated Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Amalgamated Financial’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$2.18M	Buy	+13,355	New	+$2.03M	0.02%	863

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Financial's ALNY Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2022: 13,355 shares worth $2.18M. The stake represents 0.02% of the portfolio and ranks #863 among its holdings.

444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

Amalgamated Financial held 13,355 shares of Alnylam Pharmaceuticals worth $2.18M as of Q1 2022.
Alnylam Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Alnylam Pharmaceuticals made up 0.02% of Amalgamated Financial's portfolio in Q1 2022, its #863 holding.
444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.